Study guide

7.4 Neurologic, Breast, and Neuroendocrine PET Agents

Certified Nuclear Medicine Technologist CNMT

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 Current CNMT Exam Facts 1.2 How to Use This Guide

2 Radiation Physics Fundamentals

2.1 Radioactive Materials, Isotopes, and Decay Modes 2.2 Decay Calculations and Counting Statistics 2.3 Interactions of Radiation with Matter 2.4 Radiation Detector Types and Principles

3 Biological Effects & ALARA

3.1 Biological Effects of Radiation Exposure 3.2 ALARA and Protection Calculations 3.3 Dose Limits, Surveys, and Personal Monitoring

4 NRC & Regulatory Compliance

4.1 NRC Areas, Spills, Waste, and Records 4.2 Written Directives and DOT Shipping 4.3 EPA, OSHA, HIPAA, FDA, and USP Standards 4.4 Radioactive Waste Disposal and Regulatory Records

5 Generators & Kit Preparation

5.1 Radionuclide Generators and Quality Control 5.2 Radiopharmaceutical Kit Preparation 5.3 Radiopharmaceutical Quality Control

6 Tc-99m Diagnostic Agents

6.1 Tc-99m Cardiac Imaging Agents 6.2 Tc-99m Bone, Renal, and GU Agents 6.3 Tc-99m GI and Hepatobiliary Agents 6.4 Tc-99m CNS, Infection, and Labeled Cells

7 Non-Tc Diagnostic & PET Agents

7.1 Iodine and Indium Diagnostic Agents 7.2 Gallium, Thallium, Xenon, and Miscellaneous Agents 7.3 PET Radiopharmaceuticals 7.4 Neurologic, Breast, and Neuroendocrine PET Agents

8 Therapeutics, Adjuncts & Administration

8.1 Therapeutic Radiopharmaceuticals 8.2 Interventional and Adjunct Pharmaceuticals 8.3 Blood Labeling and Administration Techniques 8.4 Blockade, Comfort, and Gastrointestinal Adjunct Agents

9 Non-Imaging Instrumentation

9.1 Well Counters, Probes, and Survey Meters 9.2 Dose Calibrator Quality Control 9.3 Auxiliary and Patient Care Equipment

10 Imaging Systems & Quality Control

10.1 Gamma Camera Quality Control 10.2 SPECT and SPECT/CT Systems 10.3 PET and PET/CT Systems and QC 10.4 CT Systems, PACS, and Information Systems 10.5 CT Radiation Dose, Safety Alerts, and Protocol Optimization

11 Pulmonary, Bone, Oncology & Infection Imaging

11.1 Pulmonary Imaging Procedures 11.2 Bone and Musculoskeletal Imaging 11.3 Oncology Imaging Procedures 11.4 Infection Imaging Procedures

12 Renal, Endocrine & Hematopoietic Imaging

12.1 Renal and Genitourinary Imaging 12.2 Endocrine Imaging (Thyroid, Parathyroid, Adrenal) 12.3 Hematopoietic and Bone Marrow Imaging 12.4 Thyroid Uptake Measurement and Radioiodine Survey Technique

13 Cardiovascular Procedures

13.1 Myocardial Perfusion Imaging 13.2 Cardiac Function, Viability, and Special Studies 13.3 Exercise and Pharmacologic Stress Testing

14 GI, CNS, Therapy & Hybrid CT Procedures

14.1 Gastrointestinal Procedures 14.2 Central Nervous System Procedures 14.3 Radionuclide Therapy Procedures 14.4 CT and Hybrid Imaging in Nuclear Medicine 14.5 CSF Studies: Cisternography, Leak Localization, and Shunt Patency

15 Patient Care & Clinical Workflow

15.1 Patient Care, Education, and Consent 15.2 Scheduling and Radiopharmaceutical Procurement 15.3 Acquisition, Positioning, and Image Quality 15.4 Image Processing and Quantitative Analysis 15.5 Non-Imaging Studies: Specimens, Counting, and Error Analysis

7.4 Neurologic, Breast, and Neuroendocrine PET Agents

Key Takeaways Explain This Topic AI

F-18 fluorodopa is an amino-acid analog decarboxylated and stored in presynaptic vesicles; the labeled adult dose is about 5 mCi (185 MBq) with imaging roughly 75–90 minutes after injection to visualize striatal dopaminergic terminals in suspected Parkinsonian syndromes.

F-18 fluoroestradiol (Cerianna®) images estrogen-receptor-positive breast lesions; ER-blocking drugs must be discontinued for at least five biological half-lives (tamoxifen up to 8 weeks, fulvestrant up to 28 weeks) or the study reads falsely negative.

Amyloid agents (florbetapir, florbetaben, flutemetamol) bind beta-amyloid plaque, while F-18 flortaucipir binds paired-helical-filament tau—different targets, different uptake windows, and neither one alone diagnoses Alzheimer disease.

Somatostatin-receptor PET uses Ga-68 dotatate/dotatoc (Ga-68 half-life about 68 minutes, generator-produced) or Cu-64 dotatate (half-life about 12.7 hours), which ships like a unit dose instead of requiring an on-site generator.

Ga-68 gozetotide is the nonproprietary name for the Ga-68 PSMA-11 products marketed as Illuccix® and Locametz®; F-18 piflufolastat (Pylarify®) is the F-18 PSMA alternative with easier distribution logistics.

Last updated: August 2026

7.4 Neurologic, Breast, and Neuroendocrine PET Agents

Quick Answer: Fluorodopa → striatal dopaminergic terminals (≈5 mCi, image 75–90 min ). Fluoroestradiol (Cerianna®) → ER-positive breast lesions ( hold SERMs/SERDs for 5 biological half-lives ). Amyloid trio → plaque; flortaucipir → tau. Ga-68/Cu-64 dotatate → somatostatin receptors. Ga-68 gozetotide (PSMA-11) and F-18 piflufolastat → PSMA. The failure mode is almost never the camera—it is an unheld drug or a wrong uptake clock.

Section 7.3 covered the PET workhorses (FDG, NaF, cardiac perfusion) and named the broader catalog. The COPS 2024 blueprint lists every one of these agents individually, so each deserves its own mechanism, prep rule, and trap.

F-18 Fluorodopa (FDOPA)

Mechanism. Fluorodopa is a fluorinated analog of L-DOPA . It crosses the blood–brain barrier on the large neutral amino acid transporter , is decarboxylated by aromatic amino acid decarboxylase (AADC) to F-18 fluorodopamine, and is stored in presynaptic vesicles . Signal therefore reflects the integrity of presynaptic dopaminergic terminals —the same biology DaTscan interrogates from the transporter side.

Item Practice

Approved use PET visualization of dopaminergic nerve terminals in the striatum in adults with suspected Parkinsonian syndromes

  • Adult activity About 5 mCi (185 MBq) IV, infused over roughly one minute
  • Imaging window Optimal about 75–90 minutes after injection per labeling

Premedication Carbidopa pretreatment is used in some protocols (especially non-neurologic indications) to block peripheral decarboxylation and raise brain uptake—follow the site protocol

Other uses Neuroendocrine tumors, congenital hyperinsulinism, and selected brain tumors at specialized centers

Traps: confusing FDOPA (a PET, presynaptic synthesis/storage tracer) with I-123 ioflupane (a SPECT, transporter-binding tracer); imaging too early; failing to control head motion during a long striatal acquisition.

F-18 Fluoroestradiol (Cerianna®)

Mechanism. An estradiol analog that binds the estrogen receptor (ER) . It is used as an adjunct to biopsy to detect ER-positive lesions in recurrent or metastatic breast cancer.

  • Item Practice
  • Imaging start Recommended about 80 minutes after IV administration

Critical hold Discontinue ER-blocking drugs for at least five biological half-lives. Tamoxifen can occupy the receptor for up to 8 weeks ; fulvestrant for up to 28 weeks

Physiologic uptake Liver (dominant, hepatic metabolism), intestine, kidneys, bladder

Trap A patient still on a SERM or SERD produces a falsely negative study; screening the medication list is the technologist's job

Intense hepatic activity means liver metastases are the weak spot for this agent—know that limitation.

Amyloid Versus Tau

  • Agent Target Notes
  • F-18 florbetapir (Amyvid®) Beta-amyloid plaque Short uptake window; grayscale or color display per training
  • F-18 florbetaben (Neuraceq®) Beta-amyloid plaque Uptake window typically starts later than florbetapir
  • F-18 flutemetamol (Vizamyl®) Beta-amyloid plaque Color-scale reading is part of the approved training

F-18 flortaucipir (Tauvid®) Paired-helical-filament tau Different protein, different distribution (medial temporal to neocortical progression)

All four require motion-free brain PET with the head immobilized and a reconstruction that preserves gray–white contrast. Amyloid and tau agents are read by trained interpreters against approved criteria ; quantitative scales such as Centiloid support but do not replace visual reading. Amyloid-positive is not a diagnosis of Alzheimer disease.

Somatostatin-Receptor PET

Agent Nuclide half-life Logistics

Ga-68 dotatate (Netspot®) Ga-68 ≈ 68 min Ge-68/Ga-68 generator on site or regional same-day delivery; kit reconstitution and elution QC

  • Ga-68 dotatoc Ga-68 ≈ 68 min Same generator chemistry; availability varies by site
  • Cu-64 dotatate (Detectnet®) Cu-64 ≈ 12.7 h Ships as a unit dose ; no generator, wider delivery radius

Prep note: long-acting cold somatostatin analogs (octreotide LAR, lanreotide) compete for the same receptors; scheduling relative to the last therapy injection follows the protocol. These agents are also the diagnostic gate for Lu-177 dotatate therapy—receptor-positive imaging precedes peptide receptor radionuclide therapy.

PSMA-Targeted PET

Agent Nuclide Naming note

Ga-68 gozetotide (Illuccix®, Locametz®) Ga-68 Gozetotide is the nonproprietary name for the PSMA-11 ligand—expect either term on an exam item

F-18 piflufolastat (Pylarify®) F-18 (110 min) Longer half-life eases distribution to sites without a generator

Physiologic PSMA uptake in lacrimal and salivary glands, liver, spleen, small bowel, kidneys, and bladder is normal—do not treat it as disease. PSMA imaging also selects patients for Lu-177 PSMA therapy , tying §7.4 directly to §8.1.

Selection Table

  • Clinical question Agent
  • Suspected Parkinsonian syndrome, PET available F-18 fluorodopa
  • Is this recurrent breast lesion ER-positive? F-18 fluoroestradiol
  • Amyloid status in cognitive impairment Florbetapir / florbetaben / flutemetamol
  • Tau burden and distribution F-18 flortaucipir
  • Neuroendocrine tumor staging or PRRT selection Ga-68 or Cu-64 dotatate/dotatoc
  • Prostate cancer staging or recurrence Ga-68 gozetotide or F-18 piflufolastat

Bottom line: each specialty PET agent has one biological target and one prep rule that can invalidate it. Learn the pair, and the item writes itself.